Bayer Aktienges ADR (BAYRY)

$13.77 +0.36 (2.68%)
Market Cap 52.70B
Revenue (ttm) 50.43B
Net Income (ttm) -2.76B
EPS (ttm) N/A
PE Ratio 9.41
Forward PE 9.02
Profit Margin -5.48%
Debt to Equity Ratio 1.33
Volume 1,003,500
Avg Vol 880,272
Day's Range N/A - N/A
Shares Out 3.93B
Stochastic %K 96%
Beta 0.68
Analysts Strong Sell
Price Target $14.18

Company Profile

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equ...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 49 214 30 1
Address:
Kaiser-Wilhelm-Allee 1, Leverkusen, Germany
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 29 at 9:04 PM
$SLS Old AJAX buyout news - from yesterday, should give, even the most conservative of investors, great comfort, and conviction in accumulating SLS shares at $0.888B /$4.70. Ajax $2.3B purchase based on preclinical data, for heme disease - sets an absolute floor $15 , for 009 value. - 009 Newly Diagnosed Front Line AML-MR / Tp53 MOS was Not Reached in the PH2B AML-MR 1L Data published at ASH, was at least 9 months. - MOS in the Ongoing SLS009 Pivotal Randomize Expansion will be greater than the SOC - 9.7months AML-MR /3-6 month Tp53 MOS. SLS009 Related Toxicities: the Key to 009 Value, on Target Selectivity eliminates toxicity. $BAYRY
0 · Reply
TalkMarkets
TalkMarkets Apr. 27 at 11:30 AM
5 AgTech Investments That Are Actually Paying Off In 2026 $DE $ICL $AGCO $BAYRY https://talkmarkets.com/article/5-agtech-investments-that-are-actually-paying-off-in-2026-1777289414
0 · Reply
HereForFunsies
HereForFunsies Apr. 23 at 1:56 PM
$BAYRY Solicitor General being allowed to speak during SCOTUS hearing next week. MDL leadership denied. I think Bayer has some favor going into this finally. Here's to hoping it goes in Bayer's direction 🙏 not just for the investment, but for the sake of future farming and yield https://www.supremecourt.gov/docket/docketfiles/html/public/24-1068.html?utm_source=chatgpt.com
1 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Apr. 22 at 1:59 AM
$TAK IMT-009 + fruquintinib Ph1b in 3L+ MSS CRC: 5.3% ORR, 47.4% DCR, zero DLTs, only 5.3% Grade 3 events. "Silent partner" safety vs $AGEN botensilimab is the moat. TLS biomarker enrichment + Project Optimus dose-finding (240mg vs 800mg) are the required unlocks. $BAYRY #MSSCRC Read more: https://www.clinicaltrialsdaily.com/cd161-clec2d-checkpoint-inhibitor-colorectal-cancer/
2 · Reply
HereForFunsies
HereForFunsies Apr. 21 at 3:45 PM
$BAYRY dip before the SCOTUS rip?? 👀 Case starts next week. Here's to hoping it goes in our favor 🙌
0 · Reply
Dirk1969
Dirk1969 Apr. 13 at 6:24 PM
$BOLD $BAYRY Bayer, not the least, not a small fry https://www.bayer.com/media/en-us/boundless-bio-announces-100-million-oversubscribed-series-c-financing-co-led-by-leaps-by-bayer-and-ra-capital-management-to-advance-the-first-ecdna-directed-therapies-ecdtx-for-patients-with-oncogene-amplified-cancer/
0 · Reply
sideload
sideload Apr. 2 at 2:39 PM
$BAYRY $ICU $MCK $MDT $SYK
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 1 at 9:29 PM
$BAYRY
0 · Reply
optionstradeseeker
optionstradeseeker Apr. 1 at 1:22 PM
$BAYRY Apr 27th key date with SCOTUS hearing scheduled...make or break
0 · Reply
Quantumup
Quantumup Mar. 31 at 1:11 PM
H.C. Wainwright reiterated $BBIO Buy; $100 $SRPT $BAYRY ALNY PFE Here's what H.C. Wainwright had to say in its note to investors: https://x.com/Quantumup1/status/2038966597507817932?s=20
0 · Reply
Latest News on BAYRY
No data available.
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 29 at 9:04 PM
$SLS Old AJAX buyout news - from yesterday, should give, even the most conservative of investors, great comfort, and conviction in accumulating SLS shares at $0.888B /$4.70. Ajax $2.3B purchase based on preclinical data, for heme disease - sets an absolute floor $15 , for 009 value. - 009 Newly Diagnosed Front Line AML-MR / Tp53 MOS was Not Reached in the PH2B AML-MR 1L Data published at ASH, was at least 9 months. - MOS in the Ongoing SLS009 Pivotal Randomize Expansion will be greater than the SOC - 9.7months AML-MR /3-6 month Tp53 MOS. SLS009 Related Toxicities: the Key to 009 Value, on Target Selectivity eliminates toxicity. $BAYRY
0 · Reply
TalkMarkets
TalkMarkets Apr. 27 at 11:30 AM
5 AgTech Investments That Are Actually Paying Off In 2026 $DE $ICL $AGCO $BAYRY https://talkmarkets.com/article/5-agtech-investments-that-are-actually-paying-off-in-2026-1777289414
0 · Reply
HereForFunsies
HereForFunsies Apr. 23 at 1:56 PM
$BAYRY Solicitor General being allowed to speak during SCOTUS hearing next week. MDL leadership denied. I think Bayer has some favor going into this finally. Here's to hoping it goes in Bayer's direction 🙏 not just for the investment, but for the sake of future farming and yield https://www.supremecourt.gov/docket/docketfiles/html/public/24-1068.html?utm_source=chatgpt.com
1 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Apr. 22 at 1:59 AM
$TAK IMT-009 + fruquintinib Ph1b in 3L+ MSS CRC: 5.3% ORR, 47.4% DCR, zero DLTs, only 5.3% Grade 3 events. "Silent partner" safety vs $AGEN botensilimab is the moat. TLS biomarker enrichment + Project Optimus dose-finding (240mg vs 800mg) are the required unlocks. $BAYRY #MSSCRC Read more: https://www.clinicaltrialsdaily.com/cd161-clec2d-checkpoint-inhibitor-colorectal-cancer/
2 · Reply
HereForFunsies
HereForFunsies Apr. 21 at 3:45 PM
$BAYRY dip before the SCOTUS rip?? 👀 Case starts next week. Here's to hoping it goes in our favor 🙌
0 · Reply
Dirk1969
Dirk1969 Apr. 13 at 6:24 PM
$BOLD $BAYRY Bayer, not the least, not a small fry https://www.bayer.com/media/en-us/boundless-bio-announces-100-million-oversubscribed-series-c-financing-co-led-by-leaps-by-bayer-and-ra-capital-management-to-advance-the-first-ecdna-directed-therapies-ecdtx-for-patients-with-oncogene-amplified-cancer/
0 · Reply
sideload
sideload Apr. 2 at 2:39 PM
$BAYRY $ICU $MCK $MDT $SYK
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 1 at 9:29 PM
$BAYRY
0 · Reply
optionstradeseeker
optionstradeseeker Apr. 1 at 1:22 PM
$BAYRY Apr 27th key date with SCOTUS hearing scheduled...make or break
0 · Reply
Quantumup
Quantumup Mar. 31 at 1:11 PM
H.C. Wainwright reiterated $BBIO Buy; $100 $SRPT $BAYRY ALNY PFE Here's what H.C. Wainwright had to say in its note to investors: https://x.com/Quantumup1/status/2038966597507817932?s=20
0 · Reply
HereForFunsies
HereForFunsies Mar. 23 at 10:50 PM
$BAYRY 5% after hours move on 10.21K volume, which is significant for BAYRY. Any news on what's going on?
0 · Reply
HereForFunsies
HereForFunsies Mar. 23 at 11:28 AM
$BAYRY disregard. It finally woke up lol
0 · Reply
HereForFunsies
HereForFunsies Mar. 23 at 11:18 AM
$BAYRY all US stocks booming today. And then here's this to keep me humble 😂
0 · Reply
11thestate
11thestate Mar. 20 at 1:38 PM
$BAYRY investors, if you follow us, you already know about it. This info hits different after the news. Check it out: https://11th.com/cases/bayer-investor-settlement
0 · Reply
Quantumup
Quantumup Mar. 17 at 12:45 PM
Cantor🏁 $TENX and said it sees 2-3X move if LEVEL hits Stat Sig and cut in ½ or worse on failure. $TECX $MRK $BAYRY - AZN LLY $CYTK Cantor said::We are initiating coverage of Tenax Therapeutics (TENX) with an Overweight rating and a $35 price ahead the pivotal LEVEL Phase 3 readout of TNX-103 (oral levosimendan) in PH-HFpEF expected in 3Q26. TENX is still relatively under the radar with a ~$1B fully diluted market cap, despite having a Phase 3 readout in PH-HFpEF coming in 3Q26. If LEVEL hits and is stat sig (p<0.05), we think the stock could move 2-3x. This is a high-risk, high-reward setup into the data. The setup cuts both ways: if LEVEL fails, the stock could get cut in half (or worse).
0 · Reply
AcceleratorModel
AcceleratorModel Mar. 17 at 4:11 AM
$BAYRY watching
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Mar. 16 at 5:35 PM
$SLS $SLS $SLS Just the Secondary Asset here, SLS009 is worth 5X the Entire SLS Market Value. $GILD bought $FTSV for $4.9B based on Phase 1B AML-MR Data for NEWLY DIAGNOSED PATIENTS Published at ASH. $SLS published Phase 2B AML-MR Data at ASH 2025, for Patients that FAILED AZA+VEN that is Much Better, similar ORR and Longer Survival, without the Toxicity - again In an AzaVEN Failed Setting, vs Newly DXD. Big Pharma's Know SLS009 is already worth 5X the entire SLS Market Cap - $BAYRY $ABBV have been trying to Develop a CDKinase Inhibtor for AML for Over a Decade, they've all Been TOXIC -- 009 is the First Ever Safe CDK9 Inhibitor, Ever. 80 Patient p1 7Patient p2 .... Rinvoq - Kisquali - Verzenio .... all kinase inhibitors worth tens of billions.
0 · Reply
11thestate
11thestate Mar. 13 at 12:05 PM
$BAYRY investors — there's no hidden secret here. Just one thing you really need to know. Here's how to handle your losses. More importantly, how to either recover them or risk losing even more: https://11th.com/cases/bayer-investor-settlement
0 · Reply
sideload
sideload Mar. 10 at 7:52 PM
$BAYRY $ICU $MCK $MDT $SYK
0 · Reply
HereForFunsies
HereForFunsies Mar. 10 at 11:17 AM
$BAYRY analyst upgrades will get us back over support today, here's to hoping we hold and move back into the pattern. Upward to 12.80s 🤞
0 · Reply
Broview
Broview Mar. 7 at 2:36 AM
$BAYRY less impact from Iran?
0 · Reply
ZacksResearch
ZacksResearch Mar. 5 at 6:49 PM
$BAYRY just cleared a key hurdle in its long-running Roundup saga. The company secured preliminary Missouri court approval for a proposed Roundup class settlement, an important step toward managing ongoing glyphosate litigation and future liabilities. ⚖️ Discover what this development could mean for the company 👉 https://www.zacks.com/stock/news/2879656/bayer-advances-roundup-settlement-with-missouri-court-approval?cid=sm-stocktwits-2-2879656-teaser-36240&ADID=SYND_STOCKTWITS_TWEET_2_2879656_TEASER_36240
0 · Reply